First non-hormonal remedy approved for menopausal hot flashes

July 1, 2013

(HealthDay)—Brisdelle (paroxetine) has been approved by the U.S. Food and Drug Administration as the first non-hormonal treatment to treat hot flashes associated with menopause.

All prior FDA-approved drugs for hot flashes contain either the alone or the hormonal combination of estrogen and progestin, the agency said in a news release.

Brisdelle's active ingredient is paroxetine, in a smaller amount than the same active ingredient in the antidepressant Paxil. It's not understood how paroxetine treats hot flashes, the FDA said.

Hot flashes affect up to 75 percent of all women, and can linger for as long as five years. Brisdelle's safety and effectiveness in treating the condition were evaluated in clinical studies involving 1,175 post-menopausal women with moderate-to-severe hot flashes. The most common side effects of the once-daily drug were headache, fatigue and nausea/vomiting.

Paroxetine, a (SSRI), has the same boxed label warning as other in its class. The label warns of possible increased risk of suicide among children and young adults.

Brisdelle's label also warns of a possible reduction in the effectiveness of tamoxifen—a drug prescribed to treat breast cancer—if both medications are taken together. Other potential serious side effects include increased risk of bleeding and developing a condition called serotonin syndrome, the FDA said.

Brisdelle is marketed by Noven Therapeutics, based in Miami, Fla.

Explore further: Hot flashes can come back after SSRI

More information: To learn more about this approval, visit the FDA.

Related Stories

Hot flashes can come back after SSRI

October 24, 2012
Hot flashes and night sweats can return after women stop using escitalopram—an antidepressant—to treat these menopause symptoms, according to a study published online this month in Menopause, the journal of the North ...

FDA approves drug for older women experiencing painful sex

February 26, 2013
(HealthDay)—The U.S. Food and Drug Administration has approved a new drug to treat postmenopausal women who experience pain during sex, the agency announced Tuesday.

It's not your imagination: Memory gets muddled at menopause

May 23, 2013
Don't doubt it when a woman harried by hot flashes says she's having a hard time remembering things. A new study published online in Menopause, the journal of The North American Menopause Society (NAMS), helps confirm with ...

High blood pressure in pregnancy may spell hot flashes later

April 3, 2013
Women who have hypertensive diseases during pregnancy seem to be at higher risk of having troublesome hot flashes and night sweats at menopause, report researchers from the Netherlands in an article published online today ...

Xgeva approved for rare, non-malignant tumor

June 13, 2013
(HealthDay)—Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.